AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth

Prostate

Volumn 76, Issue 6, 2016, Pages 597-608

  Hu, Brian R ^a   Fairey, Adrian S ^a   Madhav, Anisha ^b   Yang, Dongyun ^b   Li, Meng ^b   Groshen, Susan ^b   Stephens, Craig ^c   Kim, Philip H ^a   Virk, Navneet ^b   Wang, Lina ^b   Martin, Sue Ellen ^b   Erho, Nicholas ^d   Davicioni, Elai ^d   Jenkins, Robert B ^e   Den, Robert B ^f   Xu, Tong ^b   Xu, Yucheng ^b   Gill, Inderbir S ^a   Quinn, David I ^b   Goldkorn, Amir ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Response Genetics Inc   (United States)

^d GenomeDx Biosciences Inc   (Canada)

^e MAYO CLINIC   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

AXIN2; biomarker; cancer stem like cells; prostate cancer; radical prostatectomy

Indexed keywords

HERMES ANTIGEN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; SMALL INTERFERING RNA; AXIN; AXIN2 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXIN2 GENE; CANCER RECURRENCE; CANCER SURVIVAL; CD44 GENE; CELL PROLIFERATION; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DRUG RESISTANCE; EXTERNAL VALIDITY; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; POU5F1 GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; SELF RENEWAL; TACSTD2 GENE; TUMOR GROWTH; TUMOR INVASION; VALIDATION PROCESS; AGED; CANCER GRADING; CANCER STAGING; GENETICS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TUMOR RECURRENCE;

AGED; AXIN PROTEIN; BIOMARKERS; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84960406240     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23151     Document Type: Article

References (52)

1. SEER Cancer Statistics Factsheets: Prostate Cancer. National Cancer Institute. Bethesda, MD. www.seer.cancer.gov/statfacts/html/prost.html
2. Li J, Djenaba JA, Soman A, Rim SH, Master VA,. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 2012; 2012: 691380.
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-523.
4. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW,. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23 (28): 7005-7012.
5. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Jr., Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT,. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27 (26): 4300-4305.
6. Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T,. The role of genetic markers in the management of prostate cancer. Eur Urol 2012; 62 (4): 577-587.
7. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Hoyer S, Orntoft TF, Sorensen KD,. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013; 31 (26): 3250-3258.
8. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR,. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013; 31 (11): 1428-1434.
9. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J,. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Eng J Med 2014; 371 (11): 1028-1038.
10. Xu T, He K, Wang L, Goldkorn A,. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate 2011; 71 (13): 1390-1400.
11. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65 (23): 10946-10951.
12. Desai B, Rogers MJ, Chellaiah MA,. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007; 6: 18.
13. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA,. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133 (4): 704-715.
14. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA,. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40 (5): 499-507.
15. He K, Xu T, Goldkorn A,. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther 2011; 10 (6): 938-948.
16. He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A,. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/beta-catenin/CBP pathway. Int J Cancer 2014; 134 (1): 43-54.
17. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA,. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011; 108 (19): 7950-7955.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97 (16): 1180-1184.
19. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A,. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997; 49 (3A Suppl): 23-30.
20. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, Danenberg PV, Rosell R,. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8 (7): 2286-2291.
21. Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP,. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2014; 89 (5): 1038-1046.
22. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB,. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 2013; 8 (6): e66855.
23. Piccolo SR, Sun Y, Campbell JD, Lenburg ME, Bild AH, Johnson WE,. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics 2012; 100 (6): 337-344.
24. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM,. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9 (2): 166-180.
25. Goldkorn A, Blackburn EH,. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res 2006; 66 (11): 5763-5771.
26. Gossen M, Bujard H,. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89 (12): 5547-5551.
27. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18 (1): 11-22.
28. Bittner M., International Genomics Consortium. www.intgen.org/expo; 2005.
29. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR,. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101 (3): 811-816.
30. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G, Becich M,. Gene expression analysis of prostate cancers. Mol Carcinog 2002; 33 (1): 25-35.
31. Vanaja DK, Cheville JC, Iturria SJ, Young CY,. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63 (14): 3877-3882.
32. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA,. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487 (7406): 239-243.
33. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM,. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8 (5): 393-406.
34. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA,. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7: 64.
35. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H,. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007; 67 (11): 5117-5125.
36. Shi X, Gipp J, Dries M, Bushman W,. Prostate progenitor cells proliferate in response to castration. Stem Cell Res 2014; 13 (1): 154-163.
37. Matchett KB, Lappin TR,. Concise reviews: cancer stem cells: from concept to cure. Stem Cells 2014; 32 (10): 2563-2570.
38. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C,. Analytical validation of the Oncotype DX prostate cancer assay-a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 2013; 14: 690.
39. Liu C, Li Z, Bi L, Li K, Zhou B, Xu C, Huang J, Xu K,. NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells. Mol Cell Biochem 2014; 393 (1-2): 265-270.
40. Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, Kearsley JH, Li Y,. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate 2014; 74 (6): 602-617.
41. Marin-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernandez PL, Pereira MV, Jimenez N, Donovan M, Puig P, Mengual L, Bermudo R, Font A, Gallardo E, Ribal MJ, Alcaraz A, Gascon P, Mellado B,. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther 2014; 13 (5): 1270-1284.
42. Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjalm-Eriksson M, Harmenberg U, Cedermark GC, Andersson K, Ahrlund-Richter L, Pramana S, Pawitan Y, Nister M, Nilsson S, Li C,. An expression signature at diagnosis to estimate prostate cancer patients' overall survival. Prostate Cancer Prostatic Dis 2014; 17 (1): 81-90.
43. Markert EK, Mizuno H, Vazquez A, Levine AJ,. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 2011; 108 (52): 21276-21281.
44. Klaus A, Birchmeier W,. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8 (5): 387-398.
45. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F,. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461 (7264): 614-620.
46. Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN,. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 2000; 26 (2): 146-147.
47. Bao R, Christova T, Song S, Angers S, Yan X, Attisano L,. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS ONE 2012; 7 (11): 48670.
48. Wu ZQ, Brabletz T, Fearon E, Willis AL, Hu CY, Li XY, Weiss SJ,. Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc Natl Acad Sci USA 2012; 109 (28): 11312-11317.
49. Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, Cha SY, Ryu JK, Choi YJ, Kim J, Fearon ER, Weiss SJ,. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 2006; 8 (12): 1398-1406.
50. Ontiveros CS, Salm SN, Wilson EL,. Axin2 expression identifies progenitor cells in the murine prostate. Prostate 2008; 68 (12): 1263-1272.
51. Pinarbasi E, Gunes EG, Pinarbasi H, Donmez G, Silig Y,. AXIN2 polymorphism and its association with prostate cancer in a Turkish population. Med Oncol 2011; 28 (4): 1373-1378.
52. Ma C, Liu C, Huang P, Kaku H, Chen J, Guo K, Ueki H, Sakai A, Nasu Y, Kumon H, Shimizu K, Watanabe M,. Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer. Oncol Lett 2014; 8 (2): 789-794.